HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rodolfo Montironi Selected Research

Inverted Papilloma

7/2016Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
8/2013Human papillomavirus is not an etiologic agent of urothelial inverted papillomas.
3/2013Telomere shortening distinguishes inverted urothelial neoplasms.
12/2007Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.
12/2006Natural history of urothelial inverted papilloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rodolfo Montironi Research Topics

Disease

221Neoplasms (Cancer)
05/2022 - 01/2002
133Prostatic Neoplasms (Prostate Cancer)
05/2022 - 03/2003
82Carcinoma (Carcinomatosis)
05/2022 - 01/2004
63Renal Cell Carcinoma (Grawitz Tumor)
01/2022 - 01/2009
45Urinary Bladder Neoplasms (Bladder Cancer)
04/2022 - 06/2003
33Adenocarcinoma
01/2022 - 01/2004
25Neoplasm Metastasis (Metastasis)
02/2022 - 03/2002
24Prostatic Intraepithelial Neoplasia
01/2021 - 06/2002
14Margins of Excision
01/2020 - 01/2004
13Carcinogenesis
01/2021 - 04/2006
11Kidney Neoplasms (Kidney Cancer)
01/2020 - 05/2008
10Circulating Neoplastic Cells
11/2021 - 01/2017
8Disease Progression
08/2019 - 10/2008
5Non-Muscle Invasive Bladder Neoplasms
11/2021 - 01/2017
5Noninfiltrating Intraductal Carcinoma (DCIS)
03/2021 - 03/2013
5Carcinoma in Situ
03/2021 - 12/2005
5Inverted Papilloma
07/2016 - 12/2006
5Atrophy
10/2010 - 10/2007
4Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
01/2021 - 06/2002
4Testicular Neoplasms (Testicular Cancer)
01/2021 - 09/2015
4Inflammation (Inflammations)
10/2020 - 07/2011
4Hyperplasia
11/2019 - 04/2005
4Small Cell Carcinoma
12/2018 - 02/2007
4Urogenital Neoplasms
09/2016 - 01/2015
4Lymphatic Metastasis
04/2011 - 03/2002
3Glandular and Epithelial Neoplasms (Neoplasms, Glandular)
05/2022 - 01/2009
3Melanoma (Melanoma, Malignant)
01/2022 - 02/2013
3Breast Neoplasms (Breast Cancer)
02/2021 - 04/2006
3Obesity
11/2019 - 05/2010
3Cystitis
07/2016 - 11/2006
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/2015 - 11/2012

Drug/Important Bio-Agent (IBA)

59Biomarkers (Surrogate Marker)IBA
02/2022 - 09/2003
45Biological ProductsIBA
05/2022 - 03/2002
32Proteins (Proteins, Gene)FDA Link
12/2020 - 03/2002
22Immune Checkpoint InhibitorsIBA
02/2022 - 04/2016
19Hormones (Hormone)IBA
01/2022 - 04/2003
18AndrogensIBA
01/2022 - 01/2004
16Androgen Receptors (Androgen Receptor)IBA
02/2022 - 06/2002
15DNA (Deoxyribonucleic Acid)IBA
01/2022 - 04/2005
15Prostate-Specific Antigen (Semenogelase)IBA
11/2019 - 06/2002
13Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2021 - 11/2013
12AntigensIBA
02/2021 - 11/2006
9Tyrosine Kinase InhibitorsIBA
01/2022 - 04/2011
8ParaffinIBA
11/2019 - 04/2005
8ChromatinIBA
10/2015 - 09/2003
7Phenobarbital (Luminal)FDA Link
11/2021 - 06/2002
7ErbB Receptors (EGF Receptor)IBA
01/2014 - 02/2007
6AntibodiesIBA
02/2021 - 12/2007
6Cell-Free Nucleic AcidsIBA
01/2020 - 01/2018
6Sunitinib (Sutent)FDA Link
01/2019 - 11/2013
6PlatinumIBA
01/2019 - 01/2005
6Succinate Dehydrogenase (Fumarate Reductase)IBA
09/2016 - 10/2013
6Somatostatin Receptors (Somatostatin Receptor)IBA
01/2013 - 01/2008
5Poly(ADP-ribose) Polymerase InhibitorsIBA
02/2022 - 01/2020
5Circulating Tumor DNAIBA
05/2021 - 01/2019
5Formaldehyde (Formol)FDA Link
11/2019 - 04/2005
5Keratin-20 (Cytokeratin 20)IBA
01/2017 - 11/2006
4enzalutamideIBA
05/2022 - 03/2015
4VimentinIBA
01/2022 - 10/2013
4cabozantinibIBA
01/2021 - 10/2018
4Cisplatin (Platino)FDA LinkGeneric
01/2021 - 01/2008
4Telomerase (Telomerase Reverse Transcriptase)IBA
01/2021 - 01/2004
4Indicators and Reagents (Reagents)IBA
07/2020 - 04/2006
4Docetaxel (Taxotere)FDA Link
03/2020 - 09/2009
4MicroRNAs (MicroRNA)IBA
01/2020 - 10/2017
4pazopanibFDA Link
10/2018 - 12/2014
4Racemases and Epimerases (Epimerases and Racemases)IBA
07/2016 - 10/2007
4EnzymesIBA
04/2016 - 04/2007
4Pharmaceutical PreparationsIBA
09/2015 - 10/2006
4Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA
01/2015 - 02/2008
4Anaplastic Lymphoma KinaseIBA
05/2014 - 07/2013
4alpha-methylacyl-CoA racemaseIBA
04/2014 - 02/2007
4bicalutamide (Casodex)FDA LinkGeneric
04/2009 - 01/2004
3LigandsIBA
02/2022 - 12/2018
3NivolumabIBA
07/2021 - 01/2016
3Tumor Biomarkers (Tumor Markers)IBA
03/2021 - 01/2005
3B7-H1 AntigenIBA
01/2021 - 03/2018
3Chimeric Antigen ReceptorsIBA
01/2021 - 01/2020
3CytokinesIBA
10/2020 - 08/2016
3Monoclonal AntibodiesIBA
01/2020 - 03/2012
3RNA (Ribonucleic Acid)IBA
01/2020 - 09/2007
3Death Domain ReceptorsIBA
01/2020 - 03/2018
3Genetic Markers (Genetic Marker)IBA
10/2017 - 03/2008
3Uroplakin IIIIBA
04/2017 - 04/2008
3Fluconazole (Zonal)FDA LinkGeneric
12/2016 - 01/2011
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2016 - 03/2014
3Cyclin D3IBA
01/2016 - 09/2004
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2015 - 04/2007
3Complementary DNA (cDNA)IBA
01/2015 - 09/2008

Therapy/Procedure

126Therapeutics
05/2022 - 04/2003
70Prostatectomy (Retropubic Prostatectomy)
01/2022 - 01/2002
32Immunotherapy
01/2022 - 01/2016
24Castration
05/2022 - 03/2011
24Drug Therapy (Chemotherapy)
02/2022 - 01/2008
14Radiotherapy
03/2021 - 06/2002
12Cystectomy
04/2022 - 06/2003
12Precision Medicine
01/2020 - 03/2012
12Nephrectomy
01/2019 - 06/2008
8Lymph Node Excision (Lymph Node Dissection)
11/2019 - 05/2005
3Lasers (Laser)
01/2021 - 03/2008